




ANTHONY N. DEMARIA, MD,
BRUNO COTTER, MD, KOJI OHMORI, MD
San Diego, California
The ability to opacify the central circulation with dense
ultrasonic reflectances after the injection of a variety of fluids,
so-called contrast echocardiography, was described in 1968 (1).
Since that time, the history of contrast echocardiography has
been characterized by cycles of enormous expectations and
subsequent disappointment. The enthusiasm generated by the
initial description of contrast opacification was rapidly blunted
by the realization that the contrast effect was removed during
transit through the lungs, thereby preventing visualization of
the left-sided chambers. Years later, the development of
first-generation ultrasound contrast agents that could cross the
lungs, such as sonicated serum albumin, promised to com-
pletely delineate the left ventricular endocardium on echocar-
diogram in all patients. However, left ventricular opacification
was incomplete or absent in a significant percentage of patients
undergoing such contrast studies. Even the demonstration that
intracoronary administration of contrast agents could opacify
the myocardium in patients and provide important clinical
information concerning myocardial viability (2) and the no-
reflow phenomenon (3) was offset by the difficult logistics of
performing the procedure.
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A group of second-generation ultrasound contrast agents
has recently been developed with sufficiently long persistence
time as microbubbles to achieve myocardial opacification after
intravenous injection (4). These agents have primarily utilized
perfluorocarbon gases, which have the properties of high
density and low diffusivity and saturation concentration. In
conjunction with refined recording techniques such as second
harmonic and electrocardiogram (ECG) gated imaging, i.v.
administration of these agents has visualized myocardial opaci-
fication and delineated perfusion defects in the experimental
laboratory (5). In fact, an early study demonstrated a close
concordance of myocardial contrast echocardiography with
sestamibi single photon emission computed tomography
(SPECT) examination in recognizing impaired myocardial
reserve in patients with coronary stenoses (6). With the
availability to cardiologists accomplished by FDA approval of
one of these agents (Optison; Molecular Biosystems, Inc., San
Diego, California) in January 1998, we run the risk of entering
another cycle of unrealistic, and thus unfulfilled, expectations
that contrast echocardiography can be immediately applied to
detect coronary artery disease in the routine clinical setting.
In this issue of the Journal, Marwick et al. (6) report the
first multicenter clinical trial of myocardial contrast echocar-
diography (MCE). They studied the ability of one of the
second-generation perfluorocarbon agents (NC100100; Ny-
comed AS, Oslo, Norway) to identify perfusion defects in
postmyocardial infarction patients. The results of this study
demonstrate limitations in the ability of MCE to provide data
of comparable accuracy to radionuclide scintigraphy for this
application. The feasibility of obtaining high-quality images
reached a maximum of 72% using the highest dose of the agent
with ECG-triggered, second-harmonic imaging. These MCE
recordings yielded a sensitivity and specificity of 26% and 77%,
respectively, in comparison with sestamibi SPECT imaging in
segments with adequate gain and quality recordings. On the
basis of these findings, the authors conclude that further
developments will be required to fulfill the expectations of
MCE as a clinical tool.
As acknowledged by the authors, their article has numerous
limitations. The study was performed by echocardiographers
with little experience or expertise in MCE. It is difficult to
argue that researchers inexperienced with a new technology
can best define the true utility of the technique. Surgeons and
interventional cardiologists would not likely be willing to assess
the efficacy of their procedures based upon the outcomes of
physicians performing them for the first time. The results are
applicable to unprocessed images produced by only one ultra-
sonic contrast agent. The results may have been influenced by
inherent difficulties in precisely orienting SPECT and echocar-
diographic tomograms to ensure comparison of identical seg-
ments. Moreover, quantitative criteria were applied to SPECT
images whereas those used for echo were entirely qualitative.
Finally, the low incidence of wall motion abnormalities in
patients exhibiting SPECT defects calls into question the
significance of the radionuclide findings.
The most significant limitation of the study by Marwick et
al. (6) is the absence of a clearly defined optimal methodology
by which to perform the procedure. At the current time, many
questions remain unanswered regarding the best technique for
MCE. It is not certain if individual microbubble preparations
differ in the ability to achieve myocardial opacification, nor
what is the optimal dose for these agents. Although triggered,
harmonic imaging thus far appears to yield the greatest
myocardial contrast intensity, it is not clear that imaging at
fundamental frequencies cannot accomplish MCE. Neither
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have the preferred phase (systole vs. diastole) or frequency
(one, two, four, etc.) of gating of cardiac cycles been defined.
At this time, nearly all experience with MCE reported has
utilized gray-scale tissue imaging, but the application of power
Doppler recordings may provide significantly better visualiza-
tion. No agreement exists regarding the instrument settings
(gain, dynamic range, etc.) that yield the highest quality
images. Of particular significance, the power setting that
achieves the best balance between the contrast amplitude
recorded and microbubble destruction produced remains spec-
ulative. The optimal method by which to process (e.g., subtrac-
tion) and display (e.g., color encoding) the echocardiographic
data after acquisition continues to be studied. Finally, contro-
versy continues regarding the best method to quantitatively
analyze contrast echo data, whereas the range of normal
findings and specific criteria by which to identify abnormalities
remains undefined.
Obviously, much work needs to be done before contrast
echocardiography is ready for routine clinical application to
assess myocardial perfusion. It therefore seems a bit premature
to compare MCE with radionuclide studies in the absence of
having established the optimal technique for image acquisition
and processing, the range of normal findings and specific
diagnostic criteria. However, unjustified though it may be, the
techniques applied in the Marwick et al. (6) article are likely an
accurate reflection of what soon will be occurring in clinical
laboratories throughout the world.
The results of the study in this issue of the Journal are in
disagreement with two earlier reports. Publications by Kaul et
al. (7) and Porter et al. (8) found a good correlation of i.v.
MCE and dipyridamole radionuclide imaging in patients with
known or suspected coronary artery disease. As pointed out by
Marwick et al. (6), these two reports emanated from individual
(rather than multiple) laboratories in which experienced echo-
cardiographers had a strong commitment to contrast echocar-
diography. In addition, these other studies utilized vasodilator
stimulation, postprocessing of images and quantitation of
videointensity. The ease with which typical echocardiography
laboratories can incorporate these techniques and reproduce
the results reported remains uncertain. However, the studies
using dipyridamole stress MCE provides clear evidence of the
ultimate potential of MCE to assess perfusion abnormalities in
patients with coronary artery disease.
As has occurred before with cardiac ultrasound, the prom-
ise of deriving important new clinical data from myocardial
contrast echocardiography has led to unrealistic expectations.
Many clinicians have anticipated that achieving myocardial
opacification by i.v. injection in animals would immediately
lead to the ability to detect perfusion defects in patients. Such
expectations have been encouraged by the publication of
studies in humans reporting a good correlation of MCE with
sestamibi SPECT. However, as evidenced by the findings of
Marwick et al. (6), initial experience with intravenous MCE in
humans has yielded images of lesser quality than those in
animals. This experience has emphasized the necessity of
defining the optimal methodology to be followed in perform-
ing, processing and interpreting MCE, issues that remain
largely unsettled. A second-generation perfluorocarbon-based
ultrasonic contrast agent (Optison) has recently been approved
that provides excellent left ventricular cavity opacification of
value in routine use today, and has the attributes to visualize
abnormalities of myocardial perfusion in clinical laboratories
in the future. It would be a tragedy if the inappropriate
expectations for MCE led to disappointment with, and rejec-
tion of, the technique before its true clinical potential could be
realized.
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